PIH1 ASSOCIATION BETWEEN CENTRAL PRECOCIOUS PUBERTY AND COMORBID MEDICAL ILLNESS: LARGE-SCALE RETROSPECTIVE CLAIMS ANALYSIS OF FLORIDA MEDICAID-ENROLLED CHILDREN  by Hankin, C et al.
INDIVIDUAL’S HEALTH—Clinical Outcomes Studies
PIH1
ASSOCIATION BETWEEN CENTRAL PRECOCIOUS PUBERTY
AND COMORBID MEDICAL ILLNESS: LARGE-SCALE
RETROSPECTIVE CLAIMS ANALYSIS OF FLORIDA
MEDICAID-ENROLLED CHILDREN
Hankin C1, Silverman L2,Wang Z1, Bronstone A1
1BioMedEcon, Moss Beach, CA, USA, 2Goryeb Children’s Hospital,
Morristown, NJ, USA
OBJECTIVES: Central precocious puberty (CPP) causes prema-
ture childhood development of secondary sexual characteristics
and accelerated growth and bone maturation. A small body of
research links CPP with increased risk for CNS and congenital
disorders, but little is known about the association of CPP with
other medical conditions. We examined potential associations.
METHODS: Seven-year (1997–2004) analysis of Florida
Medicaid-enrolled children comparing those aged 3–7 years with
precocious puberty (ICD-9 259.1, which may include premature
adrenarche) to those without (age-, sex-, race-, year-, disease
burden-matched). ICD-9 diagnoses were used to classify disease
groups and disease burden (Charlson Index). Fisher’s exact test
examined differences between groups and logistic regression
examined likelihood estimates. RESULTS: Among 720,931
children, 1,644 (0.23%) were diagnosed with CPP. There
was a signiﬁcant difference in disease burden between groups
(p < 0.0001). After adjustments, compared to Medicaid-enrolled
children without the disorder, those with CPP were 6 times more
likely to be diagnosed with hemiplegia (OR 6.3, 95% CI 3.8–
10.4, p < 0.0001); 5 times more likely to be diagnosed with
cerebrovascular disease (OR 5.1, 95% CI 3.2–8.1, p < 0.0001)
or moderate or severe renal disease (OR 4.7, 95% CI 2.2–9.9,
p < 0.0001); 4 times more likely to be diagnosed with congestive
heart failure (OR 3.9, 95% CI 2.1–7.0, p < 0.0001), connective
tissue disease (OR 3.7, 95% CI 1.4–9.8, p = 0.009), or diabetes
(OR 3.5, 95% CI 2.0–6.2, p < 0.0001); and 3 times more likely
to be diagnosed with chronic pulmonary disease (OR 3.1, 95%
CI 2.2–4.3, p < 0.0001) or AIDS (OR 2.8, 95% CI 1.6–4.9,
p = 0.0002). CONCLUSION: This is the ﬁrst large-scale analysis
to show an association between ICD-9 claims-based diagnoses of
CPP and medical comorbidities. The pathways by which these
comorbid conditions may co-occur remain unclear. Given the
potential for complex medical comorbidity, patients with CPP
may beneﬁt from thorough evaluation for co-occurring medical
disorders.
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OBJECTIVES: Disease Related Malnutrition is known as a pow-
erful predictor variable for clinical outcomes in hospitalized
patients. The issue of the RAMP-Study is to describe the relation
between risk-adjusted malnutrition status and clinical outcomes
and costs. All patients have been scored simultaneously by the
two leading Scoring-Systems for malnutrion, the differences in
the predicting power of both scales for the relevant clinical
outcomes were pointed out. METHODS: From October 2006 to
December 2006 in a German 400-bed-hospital 941 patients have
been consecutively screened at admission by SGA (Subjective-
Global-Assessment)-Score and NRS 2002 (Nutritional-Risk-
Screening)-Score in the department of surgery and internal
medicine. Risk-Adjustment was provided by the Disease-Staging-
Scale (MEDSTAT/Thomson Healthcare, Ann Arbor MI), which
allows patient classiﬁcation by diagnosis and co morbidities
including age and gender. RESULTS: Strong correlation between
patients age and increasing risk for malnutrition for both Scores
has been pointed out. The NRS-2002-Score showed also a sig-
niﬁcant correlation with the ordinal clustered severity of disease,
provided by the Disease-Staging-Scale. A highly signiﬁcant result
could be shown in the average observed length of stay (OLOS)
for the top diagnostic categories (DxCats) MS 39 (Osteoarthritis)
and CV 14 (Coronary Artery Disease without CABG). Using the
NRS-2002-Score a signiﬁcant difference in regard to OLOS of 2
days between the two groups (12 days for non-malnourished
patients and 14 days for malnourished patients) with high eco-
nomic impact has been shown. CONCLUSION: The results of
the RAMP-Study show in a highly signiﬁcant way that there
could be done more for patients with disease-related malnutri-
tion avoiding negative clinical outcomes by detecting the malnu-
trition status early at hospital admission using patient-related
routine data and evidence-based Nutrition-Status-Scoring-
Systems. Hospitals should require a stronger focus on the Screen-
ing and Clinical Nutrition Therapy with regard to overall clinical
outcomes and costs.
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OBJECTIVES: The aim of this study is, ﬁrst, to provide a
systematic review of the international literature exploring
endometriosis costs and, second, to calculate endometriosis costs
in the US population. The review determines the level and drivers
of endometriosis costs; appraises the methodological quality
of cost studies; and proposes directions for designing future
studies of endometriosis costs. METHODS: Information about
endometriosis costs was derived from cost-of-illness analyses and
cost analyses. A data extraction form and quality appraisal form
was completed for each study. The calculation of endometriosis
costs in the US population was based on estimates of (in)direct
costs and endometriosis prevalence as derived from published
sources. All costs were expressed in 2002 US dollars. RESULTS:
The review indicated that annual health care costs and costs of
productivity loss associated with endometriosis have been esti-
mated at $2801 and $1023 per patient, respectively. Extrapolat-
ing these ﬁndings to the US population, this study calculated that
annual costs of endometriosis attained $22 billion in 2002
assuming a 10% prevalence rate among women of reproductive
age. To date, it is not possible to determine whether a medical
approach is less expensive than a surgical approach to treating
endometriosis in patients presenting with chronic pelvic pain.
Evidence of endometriosis costs in infertile patients is largely
lacking. Cost estimates were biased due to the absence of a
control group of patients without endometriosis, inadequate con-
sideration of endometriosis recurrence, and restricted scope of
costs. There is a need for more and better-designed studies that
carry out longitudinal analyses of patients until the cessation of
their symptoms or that model the chronic nature of endometrio-
sis. CONCLUSION: Our estimated costs of endometriosis in the
US population are considerable, underlining the need for further
research into cost-effective approaches to diagnosing and treating
endometriosis.
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